Compare UPST & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UPST | INSP |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2020 | 2018 |
| Metric | UPST | INSP |
|---|---|---|
| Price | $19.80 | $62.01 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 18 |
| Target Price | $31.19 | ★ $69.63 |
| AVG Volume (30 Days) | ★ 4.4M | 641.7K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 131.25 | ★ 179.43 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,043,857,000.00 | $82,050,000.00 |
| Revenue This Year | $26.45 | N/A |
| Revenue Next Year | $32.44 | $2.61 |
| P/E Ratio | $50.77 | ★ N/A |
| Revenue Growth | ★ 63.99 | 62.18 |
| 52 Week Low | $20.60 | $38.91 |
| 52 Week High | $52.10 | $147.03 |
| Indicator | UPST | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 34.96 | 37.71 |
| Support Level | N/A | $59.26 |
| Resistance Level | $24.92 | $64.70 |
| Average True Range (ATR) | 1.40 | 3.01 |
| MACD | -0.19 | -0.88 |
| Stochastic Oscillator | 2.50 | 15.66 |
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.